Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

BIVI
BioVie, Inc. Common Stock
stock NASDAQ

At Close
Jun 24, 2025 3:59:30 PM EDT
1.08USD+6.931%(+0.07)237,552
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jun 24, 2025 9:05:30 AM EDT
1.01USD0.000%(0.00)1,504
After-hours
Jun 24, 2025 4:33:30 PM EDT
1.07USD-0.926%(-0.01)5,155
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 20, 2022
08:19AM EST  BioVie Announces Treatment Of First Patient In Phase 2 Trial Of NE3107 For Treatment Of Parkinson's Disease   RTTNews
08:08AM EST  BioVie Announces Treatment Of First Patient In Phase 2 Clinical Trial Of NE3107 For The Treatment Of Parkinson's Disease   Benzinga
08:00AM EST  BioVie Announces Treatment of First Patient in Phase 2 Clinical   GlobeNewswire Inc
Dec 28, 2021
08:00AM EST  BioVie to Participate at the LifeSci Partners 11th Annual   GlobeNewswire Inc
Dec 9, 2021
09:47PM EST  BioVie Announces Partnership With The American Liver Foundation   Benzinga
08:00AM EST  BioVieAnnounces Partnership with the American Liver   GlobeNewswire Inc
Dec 1, 2021
08:14AM EST  BioVie Reports Secured Up to $25M Debt Facility With Avenue Ventures Opportunities Fund I, II   Benzinga
08:00AM EST  BioVieSecures Up to a $25.0 Million Debt Facility with   GlobeNewswire Inc
Nov 30, 2021
04:47PM EST  B. Riley Securities Maintains Buy on BioVie, Lowers Price Target to $27   Benzinga
Nov 4, 2021
08:00AM EDT  BioVieHosting Key Opinion   GlobeNewswire Inc
Nov 1, 2021
08:00AM EDT  BioVie Announces the Appointment of a New Chief Medical Officer   GlobeNewswire Inc
Oct 26, 2021
08:05AM EDT  UPDATE: BioVie Sees Initiating Patient Enrollment For NM201 Study Before End Of 2021, Sees Topline Results By Middle Of 2022   Benzinga
08:05AM EDT  BioVie Reports FDA Authorization To Initiate Phase 2 Trials Assessing NE3107's Pro-Motoric Activity In Parkinson's Disease   Benzinga
08:00AM EDT  BioVie Inc., (NASDAQ: BIVI) (BioVie or the Company) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that the FDA has authorized the company to initiate a Phase 2 study assessing NE3107s potential pro-motoric impact in Parkinsons disease patients.   GlobeNewswire Inc
Oct 19, 2021
09:26AM EDT  BioVie Sponsored Study Titled 'NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa' Posted To ClinicalTrials.Gov; Study Not Yet Recruiting   Benzinga
Oct 13, 2021
08:00AM EDT  BioVie Hosting Key Opinion Leader Webinar on Neuroinflammation and   GlobeNewswire Inc
Oct 12, 2021
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
Oct 1, 2021
07:56AM EDT  The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO   Benzinga
Sep 30, 2021
07:43AM EDT  The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug   Benzinga
Sep 29, 2021
08:13AM EDT  The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug   Benzinga
Sep 28, 2021
08:18AM EDT  The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive   Benzinga
08:16AM EDT  The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK To Develop Long-Acting HIV Treatments   Benzinga
Sep 22, 2021
08:00AM EDT  BioVie Inc., (NASDAQ: BIVI) (BioVie or the Company) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the participation of its management team at the Cantor Virtual Global Healthcare Conference to be held September 27-30, 2021.   GlobeNewswire Inc
Sep 15, 2021
04:01PM EDT  BioVie Inc., (NASDAQ: BIVI) (BioVie or the Company) a clinical-stage company developing innovative drug therapies for the treatment of neurodegenerative disorders and advanced liver disease, today announced the participation of its management team in the Oppenheimer Fall Healthcare Life Sciences & MedTech Virtual Summit September 22, 2021.   GlobeNewswire Inc
Sep 10, 2021
08:00AM EDT  The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test   Benzinga
Sep 9, 2021
08:17AM EDT  The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization   Benzinga
Aug 11, 2021
01:15PM EDT  BioVie Inc. Announces Closing of Public Offering of Common Stock   GlobeNewswire Inc
Aug 9, 2021
02:35PM EDT  Mid-Afternoon Market Update: Aterian Falls After Q2 Results; Select Interior Concepts Shares Spike Higher   Benzinga
12:22PM EDT  Mid-Day Market Update: Crude Oil Down 2.5%; Golden Nugget Online Gaming Shares Jump   Benzinga
10:55AM EDT  Mid-Morning Market Update: Markets Mixed; DISH Network Profit Beats Estimates   Benzinga
Aug 8, 2021
11:06PM EDT  BioVie Inc. (BIVI) said that it has priced its underwritten public offering of 2.50 million shares of its Class A common stock at a public offering price of $8.00 per share, for gross proceeds of $20 million, before deducting underwriting discounts, commissions and offering expenses.   RTTNews
09:29PM EDT  BioVie Inc. Announces Pricing of Public Offering of Common Stock   GlobeNewswire Inc
Aug 6, 2021
05:30PM EDT  BioVie Inc. (NASDAQ: BIVI) (BioVie or the Company), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, liver disease and certain cancers, today announced that it intends to offer shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company.   GlobeNewswire Inc
Aug 5, 2021
08:14AM EDT  BioVie Announces First Patient Enrolled in Phase 3 Study of NE3107 in Alzheimer's Disease   Benzinga
Jul 27, 2021
11:13AM EDT  BioVie Highlights Presentation Of Data On NE3107 As Treatment For Alzheimer's Disease   Benzinga
Jul 22, 2021
08:12AM EDT  BioVie To Present Rationale For Use Of NE3107 For Treatment Of Alzheimer's Disease At 2021 Alzheimer's Association International Conference   Benzinga
08:00AM EDT  BioVie to Present Rationale for use of NE3107 for the Treatment of   GlobeNewswire Inc
Jul 16, 2021
08:04AM EDT  BioVie Highlights Publication Of Article In Neurodegenerative Disease Management Summarizing Scientific Rationale For Co.'s Phase 3 Trial Of NE3107   Benzinga
08:00AM EDT  Basis for BioVies Phase 3 Clinical Trial of   GlobeNewswire Inc
Jun 29, 2021
08:00AM EDT  Development of BioVies NE3107 Asset Featured by   GlobeNewswire Inc
Jun 28, 2021
08:08AM EDT  BioVie Added To Russell Microcap Index Today   Benzinga
08:00AM EDT  BioVie Added to Russell Microcap Index   GlobeNewswire Inc
Jun 25, 2021
08:00AM EDT  BioVie Interview to Air on Bloomberg Television U.S. on the   GlobeNewswire Inc
Jun 24, 2021
08:02AM EDT  BioVie Announces First Patient Enrolled In BIV201 Phase 2b Clinical Trial For Ascites   Benzinga
08:00AM EDT  BioVie Announces First Patient Enrolled in BIV201 Phase 2b   GlobeNewswire Inc
Jun 23, 2021
08:02AM EDT  BioVie Receives FDA Guidance For Phase 3 Clinical Trial Of BIV201 In HRS-AKI; FDA Believes Results From Single Pivotal Phase 3 Trial Could Support NDA Filing   Benzinga
08:00AM EDT  BioVie Receives FDA Guidance for Phase 3 Clinical Trial of BIV201   GlobeNewswire Inc
Jun 17, 2021
04:05PM EDT  BioVie Interview to Air on Bloomberg Television U.S. on the   GlobeNewswire Inc
Jun 11, 2021
08:00AM EDT  BioVie Announces Closing of Acquisition of BioPharma Assets from   GlobeNewswire Inc
May 12, 2021
08:00AM EDT  BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neuro-degenerative disorders and certain cancers, today announced that it will host a research and development day on Wednesday, May 19, 2021 from 12:00pm 2:00pm Eastern Time.   GlobeNewswire Inc
May 10, 2021
08:24AM EDT  BioVie Announces Amended Terms For Asset Acquisition From NeurMedix; Payments At Closing To Include $3M In Cash And 8,361,308 Newly-Issued BioVie Shares, With Additional $7.3M Cash Payment Upon Phase 3 Alzheimer's Trial Meeting Primary Endpoints   Benzinga
08:20AM EDT  BioVie Announces Amended Terms for Asset Acquisition from   GlobeNewswire Inc
Apr 28, 2021
07:26AM EDT  The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping   Benzinga
07:00AM EDT  BioVie to Present at 2021 B. Riley Securities   GlobeNewswire Inc
Apr 27, 2021
04:28PM EDT  BioVie Acquires Biopharma Assets from Privately Held NeurMedix   Benzinga
Mar 11, 2021
07:00AM EST  BioVie to Present at 31st Annual Oppenheimer Healthcare Conference   GlobeNewswire Inc
Mar 9, 2021
09:16AM EST  BioVie Commences Patient Screening in Phase 2 Clinical Trial   Benzinga
Feb 19, 2021
07:00AM EST  BioVie Interview to Air on Bloomberg TV in the US on the RedChip   GlobeNewswire Inc
Feb 5, 2021
07:44AM EST  The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street   Benzinga
Feb 4, 2021
07:22AM EST  The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs   Benzinga
Feb 2, 2021
08:30AM EST  NeurMedix Obtains FDA Authorization for Pivotal Phase 3   GlobeNewswire Inc
Jan 25, 2021
02:34PM EST  BioVie Files For Mixed Shelf Of Up To $100M   Benzinga
Jan 21, 2021
08:05AM EST  The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping   Benzinga
Jan 20, 2021
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
Jan 15, 2021
10:07AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 15, 2021   Benzinga
08:41AM EST  B. Riley FBR Initiates Coverage On BioVie with Buy Rating, Announces Price Target of $47   Benzinga
Oct 30, 2020
08:00AM EDT  BioVie Interview to Air on Bloomberg International on the RedChip   GlobeNewswire Inc
Oct 29, 2020
08:00AM EDT  BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announcedthat it will participate in the B. Riley Securities Liver Disease Therapeutics Day 2020 on Thursday, October 29, 2020 at 11:00 a.m. ET.   GlobeNewswire Inc
Sep 23, 2020
08:00AM EDT  BioVie Announces Closing of Public Offering of Common Stock   GlobeNewswire Inc
Sep 18, 2020
02:31PM EDT  Mid-Afternoon Market Update: Dow Tumbles 300 Points; COMPASS Pathways Shares Spike Higher   Benzinga
12:06PM EDT  Mid-Day Market Update: Nasdaq Turns Lower; Westport Fuel Systems Shares Surge   Benzinga
10:17AM EDT  Mid-Morning Market Update: Markets Mixed; US Consumer Sentiment Rises In September   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC